What is Noble Financial's Forecast for GLSI Q3 Earnings?

Key Points

• Noble Financial predicts that Greenwich LifeSciences will report a Q3 2025 earnings per share of ($0.36), maintaining an "Outperform" rating with a target price of $45.00.
• The company's recent earnings report showed a loss of ($0.30) EPS, which was below analysts' expectations of ($0.24) EPS.
• Institutional investors have been increasing their stakes in Greenwich LifeSciences, with notable investments from JPMorgan Chase & Co. and Rhumbline Advisers.

Greenwich LifeSciences, Inc. (NASDAQ:GLSI - Free Report) - Analysts at Noble Financial issued their Q3 2025 earnings per share (EPS) estimates for Greenwich LifeSciences in a report released on Wednesday, August 20th. Noble Financial analyst R. Leboyer forecasts that the company will earn ($0.36) per share for the quarter. Noble Financial has a "Outperform" rating and a $45.00 price target on the stock. The consensus estimate for Greenwich LifeSciences' current full-year earnings is ($0.80) per share. Noble Financial also issued estimates for Greenwich LifeSciences' Q4 2025 earnings at ($0.34) EPS, FY2025 earnings at ($1.25) EPS, Q1 2026 earnings at ($0.35) EPS, Q2 2026 earnings at ($0.36) EPS, Q3 2026 earnings at ($0.37) EPS, Q4 2026 earnings at ($0.40) EPS, FY2026 earnings at ($1.48) EPS, FY2027 earnings at ($1.47) EPS, FY2028 earnings at $3.98 EPS and FY2029 earnings at $9.90 EPS.

Greenwich LifeSciences (NASDAQ:GLSI - Get Free Report) last posted its earnings results on Thursday, August 14th. The company reported ($0.30) earnings per share for the quarter, missing the consensus estimate of ($0.24) by ($0.06).

Greenwich LifeSciences Trading Down 2.3%

Shares of GLSI stock traded down $0.28 during mid-day trading on Friday, reaching $11.65. The stock had a trading volume of 7,872 shares, compared to its average volume of 57,448. Greenwich LifeSciences has a 12-month low of $8.06 and a 12-month high of $16.50. The company has a market cap of $158.79 million, a P/E ratio of -8.57 and a beta of 1.65. The business has a 50-day simple moving average of $10.91 and a 200 day simple moving average of $10.56.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the company. Geode Capital Management LLC increased its position in shares of Greenwich LifeSciences by 1.4% in the second quarter. Geode Capital Management LLC now owns 138,982 shares of the company's stock valued at $1,261,000 after buying an additional 1,972 shares in the last quarter. Northern Trust Corp boosted its stake in shares of Greenwich LifeSciences by 17.3% during the fourth quarter. Northern Trust Corp now owns 87,423 shares of the company's stock valued at $982,000 after acquiring an additional 12,923 shares during the last quarter. Marshall Wace LLP acquired a new stake in shares of Greenwich LifeSciences during the second quarter valued at $509,000. Charles Schwab Investment Management Inc. boosted its stake in shares of Greenwich LifeSciences by 15.5% during the first quarter. Charles Schwab Investment Management Inc. now owns 19,007 shares of the company's stock valued at $181,000 after acquiring an additional 2,552 shares during the last quarter. Finally, Strs Ohio acquired a new stake in shares of Greenwich LifeSciences during the first quarter valued at $177,000. Hedge funds and other institutional investors own 4.16% of the company's stock.

Greenwich LifeSciences Company Profile

Greenwich LifeSciences, Inc, a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.